The SAHPRA fees gazetted are implementable from 23 December 2020. The fees outlined in most cases are self
explanatory, however in the case of fees payable for quality variations there are several options listed that require clarification, and hence this explanatory note is provided for this purpose.
This document is to guide applicants on the information to submit on the design and conduct of all clinical studies for veterinary products. It is intended to ensure that such studies are conducted and documented in accordance with good clinical practice. Any person who needs to conduct a clinical trial with an unregistered veterinary medicine, a new indication, or new dosage regimen of a registered veterinary medicine requires approval from the South African Health Products Regulatory Authority.
This document provides guidance on access to unregistered medicines for animal use through the provisions of Section 21 of the Medicines and Related Substances Act, 1965.
The SAHPRA is mandated to regulate the quality, safety, and efficacy of all registered medicines. Prior to
registration of a medicine, access is limited to clinical trials authorized by the Authority and may in certain
circumstances, and in accordance with Section 21 of the Act, authorize the sale of an unregistered medicine for
such purposes and in such manner and during such period as the Authority may determine. Authorization of the
importation and use of unregistered medicines used in clinical trials is also covered by this document. However,
another set of guidelines that accompanies the use of unregistered medicines together with the protocol is provided as a separate document.
The CHECKLIST is to be used for the preparation of a formal request to the office of the Chief Regulatory
Officer (CRO)/ South African Health Product Regulatory Authority (SAHPRA) for the purpose of the
meeting and should be submitted to the SAHPRA.